Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study.
Harigai M, Tanaka E, Inoue E, Tamura N, Misaki K, Azuma T, Hirata S, Hirano F, Taniguchi Y, Mitsuhashi M, Kondo M, Oribe M, Aoki K, Kadode M, Tsuritani K, Yamanaka H. Harigai M, et al. Among authors: tamura n. Mod Rheumatol. 2023 Aug 25:road082. doi: 10.1093/mr/road082. Online ahead of print. Mod Rheumatol. 2023. PMID: 37624029
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; RESEARCH investigators; REAL Study Group. Cho SK, et al. Mod Rheumatol. 2014 Jul;24(4):572-9. doi: 10.3109/14397595.2013.860695. Epub 2013 Dec 9. Mod Rheumatol. 2014. PMID: 24320747
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi: 10.1186/s13075-015-0583-8. Arthritis Res Ther. 2015. PMID: 25880658 Free PMC article. Clinical Trial.
Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: Effectiveness and safety in the first 6 months.
Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada KE, Komagata Y, Yamamura M, Kato M, Endo T, Nakaya I, Takeuchi T, Murakawa Y, Sugihara T, Saito M, Hayashi T, Furuta S, Tamura N, Karasawa K, Banno S, Endo S, Majima M, Kaname S, Arimura Y, Harigai M. Nagasaka K, et al. Among authors: tamura n. Mod Rheumatol. 2023 Nov 1;33(6):1117-1124. doi: 10.1093/mr/roac150. Mod Rheumatol. 2023. PMID: 36478050
Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI).
Misaki K, Tanaka E, Inoue E, Tamura N, Hirano F, Taniguchi Y, Sato H, Naniwa T, Oshikawa H, Yoshitama T, Takakubo Y, Suzuki Y, Himeno S, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M. Misaki K, et al. Among authors: tamura n. Mod Rheumatol. 2024 May 10:roae043. doi: 10.1093/mr/roae043. Online ahead of print. Mod Rheumatol. 2024. PMID: 38727535
Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy.
Kitamura N, Kobayashi H, Nagasawa Y, Sugiyama K, Tsuzuki H, Tanikawa Y, Ikumi N, Okada Y, Takahashi Y, Asai S, Tamura N, Ogasawara M, Kawamoto T, Kuwatsuru R, Tamaki H, Kidoguchi G, Tateishi M, Kimura M, Mochida Y, Harigane K, Shimazaki T, Koike T, Tanimura K, Kataoka H, Amano K, Yasuoka H, Takei M. Kitamura N, et al. Among authors: tamura n. Int J Rheum Dis. 2023 Jun;26(6):1058-1066. doi: 10.1111/1756-185X.14695. Epub 2023 Apr 14. Int J Rheum Dis. 2023. PMID: 37058849
In lupus cystitis, is the urinary tract dilated or obstructed?
Abe Y, Kawamata N, Makiyama A, Ashizawa T, Hayashi T, Tamura N. Abe Y, et al. Among authors: tamura n. Immun Inflamm Dis. 2023 Feb;11(2):e777. doi: 10.1002/iid3.777. Immun Inflamm Dis. 2023. PMID: 36840498 Free PMC article.
1,376 results